Intellia Therapeutics’ (NTLA) Neutral Rating Reaffirmed at Wedbush

Wedbush restated their neutral rating on shares of Intellia Therapeutics (NASDAQ:NTLA) in a research report report published on Monday morning,Benzinga reports. They currently have a $10.00 target price on the stock.

A number of other brokerages have also commented on NTLA. Citigroup cut their price target on shares of Intellia Therapeutics from $14.00 to $10.00 and set a “neutral” rating on the stock in a report on Friday, May 9th. Wolfe Research upgraded shares of Intellia Therapeutics from a “peer perform” rating to an “outperform” rating and set a $21.00 target price on the stock in a report on Monday, April 21st. HC Wainwright initiated coverage on shares of Intellia Therapeutics in a report on Wednesday, March 5th. They issued a “buy” rating and a $30.00 target price on the stock. Barclays dropped their target price on shares of Intellia Therapeutics from $55.00 to $26.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. Finally, Chardan Capital restated a “buy” rating and issued a $68.00 target price on shares of Intellia Therapeutics in a report on Friday, May 9th. Two analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Intellia Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $36.90.

Intellia Therapeutics Stock Performance

NASDAQ NTLA opened at $9.06 on Monday. The firm’s fifty day moving average price is $7.98 and its two-hundred day moving average price is $10.68. The stock has a market cap of $938.46 million, a PE ratio of -1.67 and a beta of 2.33. Intellia Therapeutics has a fifty-two week low of $5.90 and a fifty-two week high of $28.18.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($1.10) EPS for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.16. The business had revenue of $16.63 million for the quarter, compared to analyst estimates of $11.39 million. Intellia Therapeutics’s revenue for the quarter was down 42.6% on a year-over-year basis. During the same quarter last year, the firm posted ($1.12) EPS. As a group, sell-side analysts predict that Intellia Therapeutics will post -5.07 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Intellia Therapeutics

A number of institutional investors have recently added to or reduced their stakes in NTLA. Barclays PLC grew its position in Intellia Therapeutics by 17.7% in the 3rd quarter. Barclays PLC now owns 292,795 shares of the company’s stock worth $6,017,000 after purchasing an additional 44,022 shares in the last quarter. Avanza Fonder AB bought a new stake in Intellia Therapeutics in the 4th quarter worth about $421,000. SG Americas Securities LLC grew its position in Intellia Therapeutics by 85.7% in the 4th quarter. SG Americas Securities LLC now owns 44,838 shares of the company’s stock worth $523,000 after purchasing an additional 20,694 shares in the last quarter. KBC Group NV grew its position in Intellia Therapeutics by 62.4% in the 4th quarter. KBC Group NV now owns 6,093 shares of the company’s stock worth $71,000 after purchasing an additional 2,340 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its position in Intellia Therapeutics by 10.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 21,596 shares of the company’s stock worth $252,000 after purchasing an additional 2,059 shares in the last quarter. 88.77% of the stock is owned by institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.